Elizabeth Swanson, MD

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.

Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

Elizabeth A. Swanson, MD, and Raj. J. Chovatiya, MD, PhD, examine challenges in managing atopic dermatitis and explore the evolving treatment landscape.

Korey Capozza, MPH; Elizabeth A. Swanson, MD; and Taylor Capps share pearls for patients and their families managing atopic dermatitis.

Korey Capozza, MPH, highlights the importance of patient advocacy in the atopic dermatitis journey.

Raj J. Chovatiya, MD, PhD; Elizabeth A. Swanson, MD; Tina Capps; and Taylor Capps assess barriers in finding and obtaining atopic dermatitis treatments.

Elizabeth A. Swanson, MD, discusses the safety and efficacy of dupilumab in treating moderate to severe atopic dermatitis, and Taylor Capps shares her journey with dupilumab from insurance approvals through receiving treatment.

Raj J. Chovatiya, MD, PhD, reviews goals of therapy for patients with atopic dermatitis and comments on the use of various topical therapies and systemic agents for disease management.

Korey Capozza, MPH, examines the role of multidisciplinary care for patients with atopic dermatitis, and Taylor Capps shares the impact of atopic dermatitis on mental health.

Elizabeth A. Swanson, MD, provide insight on identifying the appropriate patients for various therapeutic regimens in atopic dermatitis.

Raj J. Chovatiya, MD, PhD, discusses the level of awareness of atopic dermatitis within the medical community and approaching the management of disease.

Elizabeth A. Swanson, MD, describes the burden of atopic dermatitis on the pediatric and adult patient populations.

Raj J. Chovatiya, MD, PhD, reviews the clinical manifestations and underdiagnoses of atopic dermatitis.

Korey Capozza, MPH, offers insight into changing public perception of atopic dermatitis and bridging unmet needs in the field.

Taylor and Tina Capps assess the burden of atopic dermatitis on Taylor’s life and the impact on her family.

Taylor and Tina Capps comment on Taylor’s experience of treatment regimens early on and the impact of underlying medical conditions on her atopic dermatitis.

Taylor Capps and her mother, Tina Capps, share Taylor’s initial journey with atopic dermatitis and presenting symptoms.

Closing out its discussion on atopic dermatitis, the panel considers best practices and unmet needs in the treatment landscape.

A brief discussion on when it is best to switch therapy while treating patients for atopic dermatitis.

Shared insight on the armamentarium of systemic agents available to treat atopic dermatitis.

A review of topical therapies that have been long utilized for patients with atopic dermatitis.

A brief review of patient and disease factors that inform selection of therapy for atopic dermatitis.